Apellis Pharmaceuticals Inc., a biopharmaceutical company, recently announced it is making strides in the discovery, development, and commercialization of therapeutic compounds for autoimmune and inflammatory diseases. By inhibiting the complement system, the company is able to offer EMPAVELI, a promising treatment for a range of conditions including paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy, immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy. In addition, the company is developing SYFOVRE for the treatment of geographic atrophy (GA). To further advance their mission, Apellis Pharmaceuticals is also working on APL-2006, a new treatment for wet age-related macular degeneration and GA, APL-1030, specifically designed to treat neurodegenerative diseases, and a combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. Apellis Pharmaceuticals has also formed key partnerships and agreements, including Swedish Orphan Biovitrum AB (publ) for the development and commercialization of pegcetacoplan, and a collaboration with Beam Therapeutics Inc. to utilize the company’s base editing technology for the discovery of new treatments for complement-driven diseases. Founded in 2009 and headquartered in Waltham, Massachusetts, Apellis Pharmaceuticals has shown great promise in the biopharmaceutical market.